Walk Through Survey Report of Eli Lilly and Company Research Labs, Indianapolis, Indiana, Report No. IWS-131-16.
The results of a walk through industrial hygiene survey conducted at the Eli Lilly and Company Research Laboratories (SIC-2834) in Indianapolis, Indiana were presented. The survey represented one of a series of walk through surveys in which assessments for potential occupational hazards were made of companies using recombinant DNA techniques in industrial processes. Eli Lilly's manufacturing operations in Indianapolis employed approximately 6000 persons, but the number of workers directly involved in genetic engineering technology was estimated to be minimal. The facility and programs involved in DNA recombinant techniques were evaluated for laboratory and production facility design, engineering controls, validation procedures, work practices, emergency and accident procedures, medical surveillance, environmental monitoring, and employee training and education. Established safety and health, medical, and industrial hygiene programs were in place at the time of the survey. Environmental monitoring was limited to replicate organism direct agar contact plates, air impaction onto agar plates, settling plates filled with agar, and liquid impinger techniques. Engineering controls for the recombinant DNA fermentation processes were based on the concept of containment and provided effective control of personnel exposures as well as for process contamination. The survey team found that research and production using recombinant DNA methods at Eli Lilly was proceeding in a responsible manner. Recommendations to minimize worker exposure focused on process containment, sampling protocols, and the establishment of a worker medical registry.
Division of Surveillance, Hazard Evaluations and Field Studies, NIOSH, Cincinnati, Ohio, Report No. IWS-131-16, 14 pages